Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based GVK Biosciences (GVK BIO) has provided a license of its SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA), which will be used for drug repositioning.
Subscribe to our email newsletter
The main focus of this collaboration will be to recognize alternative therapeutic indications of marketed compounds for neglected and orphan diseases.
In order to deal with the drug repurposing challenge, GVK BIO has developed a ‘Drug Repurposing Platform’ using eight different approaches, which uses data from its SAR databases (GOSTAR), Biomarker database (GOBIOM) and other public databases.
Commenting on the collaboration with USFDA, GVK BIO business development vice president Sreeni Devidas said, "The collaboration with the USFDA is a validation of the utility of GOSTAR in multiple applications."
"GVK BIO will work with the USFDA to further enhance the Repositioning and Repurposing workflow and make it available to the entire research community," Devidas added.
More than 200 scientists worked for over a decade to build the manually curated database GOSTAR, which is extensively used by pharma and biotechnology companies as well as academia.
It has more than 5 million compounds manually curated through the manual screening of over 2.5 million patents and 400,000 journals and also contains more than 18 million quantitative SAR points.
Following the integration of over fifteen individual databases, GOSTAR emerged as the final outcome, which includes the complete chemical space for ten of the popular biological targets.
In addition to this, GOSTAR also has four Toxicity and Natural Products databases.